(lp0
S'Troubling Trial Data Weighed on Agenus Inc Stock Today Motley Fool - Feb 22, 2017 Shares of Agenus Inc , a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m.Trials Of Agenus Inc  Cancer Vaccine Ends In Absolute Failure - Market ExclusiveAgenus Inc.  Plunges 16.3% on February 22 - Equities.com'
p1
aS'Better Buy: Agenus Inc. vs. Celldex Therapeutics Motley Fool - Mar 10, 2017 Agenus Inc  and Celldex Therapeutics, Inc.  bear an uncanny resemblance to each other. Both clinical-stage biotechs are focused on developing novel cancer therapies and reported clinical-trial failures with vaccine&nbsp;...'
p2
aS"Why Fret Over Agenus Inc. Q3 Results? Motley Fool - Oct 27, 2016 And that $40.8 million loss didn't come from Agenus spending money like it's going out of style. The biotech's research and development costs did increase by 17% compared to the third quarter of 2015.Company Update : Here's Why Agenus Inc Shares Are Tumbling Today - Smarter AnalystAgenus 3Q Loss Worse Than Expected  - Investopedia"
p3
aS'Agenus Inc.  Plunges 6.1% on March 21 Equities.com - Mar 21, 2017 Agenus Inc.  had a rough trading day for Tuesday March 21 as shares tumbled 6.1%, or a loss of $-0.25 per share, to close at $3.85.Buy, Sell or Hold? Analysts Approach: Oceaneering International, Inc. (OII ... - The USA CommerceThe Allianz Asset Management AG Sells 41887 Shares of Agenus Inc  - Petro Global News 24'
p4
aS'Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Feb 6, 2017 Agenus  and Alnylam Pharmaceuticals  are both clinical-stage biotechs developing drugs that hold the potential to make a big difference for patients.'
p5
aS'Four Agenus Abstracts Accepted for Presentation at the American Association ... PR Newswire  - Mar 7, 2017 LEXINGTON, Mass., March 7, 2017 /PRNewswire/ -- Agenus Inc. , an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that four abstracts on its checkpoint antibodies and&nbsp;...Investors Targeted Stock: Agenus Inc.  - Is storiesIn Volatile Markets Do Analysts Think You Should Buy Agenus Inc. ? - The De Soto Edge'
p6
aS'Agenus announces collaboration with the National Cancer Institute to evaluate ... PR Newswire  - Jan 17, 2017 LEXINGTON, Mass., Jan. 17, 2017 /PRNewswire/ -- Agenus Inc. , an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a clinical trial collaboration with the National Cancer&nbsp;...'
p7
aS'Why Investors remained confident on Agenus Inc. , Fortune Brands Home ... StockNewsJournal - 16 hours ago Agenus Inc.  have shown a high EPS growth of -3.80% in the last 5 years and has earnings decline of -29.70% yoy. Analysts have a mean recommendation of 1.80 on this stock (A rating of less than 2 means buy, hold within the 3 range, sell ...'
p8
aS'Why Agenus Inc. Stock Plummeted 44.7% in October Motley Fool - Nov 7, 2016 Shares of tiny immunotherapy developer Agenus Inc.  tumbled 44.7% in October, according to data from S&amp;P Global Market Intelligence.'
p9
aS"3 Red Flags on Agenus Inc's Balance Sheet Motley Fool - Nov 23, 2016 Most of Agenus' potential is derived from a lineup of immunotherapy drug candidates. While the drugs target an alphabet soup of some of the most promising biological mechanisms for treating various cancers, the stock has encountered turbulence in ..."
p10
a.